Those of you interested in risk and compliance topics working in the pharmaceutical and life science industry may be interested in our dedicated Compliance Newsletter. Every two month my colleague Paul Noble compiles this fine summary of latest news and trends from the FDA, EMA and discusses the implications of recently published warning letters and enforcement actions.
To this post I attached the latest issue. Among other things it covers the EU activities to combat couterfeit drugs and the ongoing reorganisation of the FDA's enforcement arm.
If you are interested in a free subscription please let us know - or simply subscribe to the ARIS GRC group.
